Investors Financial Group’s Matinas BioPharma MTNB Stock Holding History

Investors Financial Group’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,000	Closed	-$51K	–	115
2021 Q4	$51K	Sell	1,000 -600	-38%	-$32.1K	0.02%	211
2021 Q3	$104K	Buy	1,600 +700	+78%	+$30.2K	0.06%	195
2021 Q2	$35K	Hold	900	–	–	0.02%	202
2021 Q1	$47K	Buy	900 +300	+50%	+$20.1K	0.03%	191
2020 Q4	$41K	Hold	600	–	–	0.03%	163
2020 Q3	$23K	Buy	600 +400	+200%	+$15.9K	0.02%	158
2020 Q2	$8K	Buy	+200	New	+$7.67K	0.01%	149

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

CCM

Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Investors Financial Group's MTNB Position: Q1 2022 in Review

Investors Financial Group sold out of Matinas BioPharma (MTNB) in Q1 2022, closing a stake of 1,000 shares — an estimated $51K sold.

Investors Financial Group first reported a position in MTNB in Q2 2020 and held it in 7 quarters. The position peaked at $104K in Q3 2021. 56 funds tracked by Wall St. Rank hold MTNB as of Q1 2022.

Investors Financial Group reported no remaining Matinas BioPharma position as of Q1 2022 after selling out during the quarter.
Investors Financial Group sold 1,000 Matinas BioPharma shares in Q1 2022, an estimated $51K.
Investors Financial Group first reported a position in Matinas BioPharma in Q2 2020 and held it in 7 quarters.
Investors Financial Group's Matinas BioPharma position peaked at $104K in Q3 2021.
56 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2022.

Based on Investors Financial Group's 13F filing for Q1 2022.